ClinicalTrials.gg
CompletedNCT06388616Updated Nov 12, 2024

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

A Phase 1 interventional study of Balcinrenone in Hepatic Impairment, sponsored by AstraZeneca. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group.

Read the detailed description

This is an open-label, non-randomised, multicentre, parallel-group, single-dose study to examine the PK, safety, and tolerability of balcinrenone 50 mg administered orally to male and female participants with mild or moderate hepatic impairment compared with control participants with normal hepatic function. Eight participants with mild impairment and 8 participants with moderate impairment per CP classification and 8 to 12 participants with normal hepatic function matched on a group level regarding age, BMI, and sex to the impaired groups are planned for study intervention. All participants will receive a single dose of balcinrenone 50 mg on Day 1 following an overnight fast. Study intervention will be administered orally with approximately 240 mL of water.

Child-Pugh scoring will be used to determine the level of hepatic impairment. Participants will be enrolled into the following groups based on their CP classification score as determined at screening:

  • Group 1: Participants with mild hepatic impairment (CP Class A, score of 5 or 6).
  • Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).
  • Group 3: Participants with normal hepatic function matched on a group level regarding age, BMI, and sex to the impaired groups.
02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • Healthy participants
  • Balcinrenone
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 79 years of age, inclusive, at the time of signing the .

For participant with hepatic impairment:

  • Participant must have a diagnosis of chronic (≥ 6 months) and stable hepatic impairment Class A or B (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study screening, as determined by the investigator at screening and Day -1).
  • Supporting documents confirming the participant's hepatic impairment must be available; participant self-report is not acceptable; the participant must be classified by the investigator as CP Class A or B at screening.
  • Participants must be stable on a concomitant medication and/or treatment regimen (defined as not starting a new treatment/medication[s] or a change in the dosage or frequency of the concomitant medication[s] within 2 weeks prior to screening). Minor changes in dosage can be accepted at the discretion of the investigator.

For participant with normal hepatic function:

  • Participant must be medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or 12-lead ECGs, as deemed by the investigator at screening and Day -1.
  • Body weight ≥ 50 kg; within the range of 18.0 to 42.0 kg/m2 (inclusive) as measured at screening.
  • Sex: male and female.
  • Females must not be lactating and must not have a positive pregnancy test at screening and at Day -1.
  • Women of (defined as female participants who are neither permanently sterilised [hysterectomy, bilateral oophorectomy, or bilateral salpingectomy] nor ) must use a highly effective method of (described below).
  • A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Women of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 4 weeks after study intervention.
  • Highly effective methods of contraception include: sexual abstinence (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of exposure to IMP, and withdrawal [coitus interruptus], spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception), a vasectomised partner, bilateral tubal occlusion, combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system.
  • Women of nonchildbearing potential (defined as female participants who are permanently surgically sterilised [hysterectomy, bilateral oophorectomy, or bilateral salpingectomy] or postmenopausal).
  • Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of study intervention without an alternative medical cause. The following age-specific requirements apply:
  • Women \< 55 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels in the postmenopausal range.
  • Women ≥ 55 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
  • Postmenopausal status for participants with hepatic impairment based on FSH levels may be at the discretion of the investigator.
  • Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses.

Exclusion criteria

Exclusion Criteria:

  • Participant has \< 60 mL/minute/1.73 m2 as calculated by CKD-EPI.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator at screening or Day -1, or history of hypersensitivity to drugs with a similar chemical structure or class to balcinrenone.
  • History of long syndrome or any clinically significant abnormalities on 12-lead at screening or Day -1, as judged by the investigator, including but not limited to any of the following:
  • Any significant arrhythmia.
  • Conduction abnormalities (eg, Wolff Parkinson White syndrome, second degree AV block; at the discretion of the investigator).
  • Prolonged QTcF > 450 ms for participants with normal hepatic function; > 480 ms for participants with mild or moderate hepatic impairment.
  • Clinically significant PR (PQ) interval shortening (\< 120 ms) or prolongation (> 240 ms); intermittent second or third degree AV block, or AV dissociation.
  • Complete bundle branch block and/or QRS duration > 120 ms.
  • Any of the following signs or confirmation of COVID-19 infection at screening or Day -1:
  • Participant has a positive SARS-CoV-2 test result within 2 weeks prior to screening, at screening, or on Day -1.
  • Clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnoea, sore throat, fatigue) within 2 weeks prior to screening or Day -1.
  • Positive test for at screening.
  • Positive results at screening for surface antigen, hepatitis B core antibody or virus. Participants with impaired hepatic function with positive total hepatitis B core antibody or positive hepatitis C result may be included if a follow-up hepatitis B virus DNA test or follow-up hepatitis C virus RNA test is negative.
  • History or presence of clinically significant thyroid disease, in the opinion of the investigator. Participants with clinically significant TSH levels outside normal limits at screening will not be enrolled. Participants on stable thyroid replacement therapy are not excluded.
  • History or presence of clinically significant or unstable medical or psychiatric condition or disease in the opinion of the investigator.
  • Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or Day -1 or expected during the conduct of the study.
  • History of any major surgical procedure within 30 days prior to study intervention.
  • Any clinically or surgically significant condition that may affect balcinrenone absorption and/or excretion in the opinion of the investigator, including gastric restrictions and bariatric surgery (eg, gastric bypass). Uncomplicated appendectomy and hernia repair will be allowed. Uncomplicated cholecystectomy is allowed at the discretion of the investigator.
  • Judgment by the investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or if they are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Use of any medication defined as prohibited medication (see Appendix E) within 2 weeks prior to study intervention or longer if the medication has a long half-life.
  • Unable to refrain from the following for 10 hours prior to and 10 hours after study intervention: Phosphate binders (eg, aluminium hydroxide and calcium carbonanate).

Acid reducing agents (eg, ranitidine/nizatidine or proton pump inhibitors). Cholestyramine/colestipol. MRA agents (eg, spironolactone, eplerenone, finerenone).

  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days of study intervention in this study or, if known, 5 half-lives from last dose in the previous study to study intervention in this study, whichever is longest.
  • Previous enrolment in the present study. Note: participants consented and screened, but not receiving study intervention in this study or a previous Phase I study, are not excluded.
  • Participant smokes more than 10 cigarettes (ie, 1/2 pack) per day or equivalent (eg, e-vapor cigarette, pipe, cigar, chewing tobacco, nicotine patch, nicotine gum) and is unable to comply with the nicotine restrictions (Section 5.3.2) during the study.
  • Positive screen for drugs of abuse (unless participant has hepatic impairment and positive screen is due to medication[s] prescribed by physician) and/or alcohol test at screening or Day -1.
  • Receipt of blood products within 2 months prior to Day -1, plasma or donation within 1 month prior to Day -1, or any blood donation/blood loss > 500 mL within 3 months prior to Day -1.
  • Involvement of any AstraZeneca or clinical unit employee or their close relatives.
  • Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Participants with hepatic impairment are excluded from the study if any of the following criteria apply:

  • Esophageal banding within 3 months prior to Day -1 or required treatment for gastrointestinal bleeding within 6 months prior to Day -1.
  • Ascites requiring paracentesis and albumin infusion at 4-week intervals or less.
  • History of paracentesis within 30 days prior to screening.
  • Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
  • In the opinion of the investigator, any evidence of additional severe or uncontrolled systemic disease (eg, currently unstable or uncompensated renal, cardiovascular, or respiratory disease) or laboratory finding that makes it unsafe for the participant to participate in the study.
  • Presence of a hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.
  • Hepatic impairment due to non-liver disease (eg, right HF).
  • Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
  • Clinically relevant hepatic encephalopathy (Grade 2 or more) at screening or Day -1.
  • Has required new medication for hepatic encephalopathy within the 3 months prior to Day -1.
  • Platelet count \< 35 × 109/L and/or \< 1.2 × 109/L and/or \< 85 g/L.
  • Current functioning organ transplant or anticipated to receive organ transplant within 2 months of screening or Day -1.
  • Participant has had a porto-systemic shunt (including transjugular intrahepatic portosystemic shunts).
  • History of drug abuse within 1 year prior to screening.
  • History of alcohol abuse within 3 months prior to screening and/or consumes > 21 units per week for males and > 14 units per week for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  • Supine systolic BP > 160 or \<90 mmHg, and diastolic BP > 95 or \< 40 mmHg at screening or Day -1. One repeat is allowed.
  • Supine pulse rate \< 50 bpm or > 99 bpm at screening or Day -1. One repeat is allowed.
  • Cardiac bradyarrhythmia or tachyarrhythmia requiring treatment (atrial fibrillation/flutter with optimal control of ventricular rate is not excluded) at screening or Day -1.
  • Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding (frequent bleeding gums or nose bleeds) at screening or Day -1.
  • History of unstable diabetes mellitus as evidenced by ≥ 9% at screening.

Participants with normal hepatic function are excluded from the study if any of the following criteria apply:

  • History of any clinically important disease or disorder, which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of dose administration.
  • Any laboratory values with the following deviations at screening or Day -1

    (1 confirmatory repeat is allowed):

  • and/or AST > 1.2 × .
  • White blood cell count and/or platelet count \< lower limit of normal; haemoglobin \< 11.0 g/dL for females or \< 12.0 g/dL for males.
  • Activated partial thrombin time and (or INR) > 1.2 × ULN.
  • > 1.5 × ULN (or known Gilbert's syndrome).
  • Changes in any current medication (initiation, dose change, or cessation), that may impact the study readouts (as judged by the investigator) within 2 weeks prior to screening and until study intervention. This criterion does not apply to medication prescribed for occasional use.
  • History or presence of hepatic disease or evidence of other known forms of known chronic liver disease, eg, alcoholic liver disease, hepatitis B, hepatitis C, primary biliary cirrhosis, primary sclerotic cirrhosis, hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma.
  • History of drug abuse within 2 years prior to screening.
  • History of alcohol abuse within 2 years prior to screening and/or consumes > 21 units per week for males and > 14 units per week for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  • Supine systolic BP > 150 or \< 90 mmHg, and diastolic BP > 95 or \< 50 mmHg at screening or Day -1. One repeat is allowed.
  • Supine pulse rate \< 45 bpm or > 100 bpm at screening or Day -1. One repeat is allowed.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects with Mild Impairment will receive a single oral dose of balcinrenone under fasted conditions.

    Drug: Balcinrenone

  • Experimental
    Group 2

    Subjects with Moderate Impairment will receive a single oral dose of balcinrenone under fasted conditions.

    Drug: Balcinrenone

  • Experimental
    Group 3

    Healthy participants will receive a single oral dose of balcinrenone under fasted conditions.

    Drug: Balcinrenone

Interventions

  • 50 mg, Immediate release capsule to be taken orally.

    Also known as: AZD9977

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time zero to the last measurable concentration (AUClast)

    To compare the PK of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment to those with normal hepatic function

    Time frame: Day 1 to Day 5

  2. Area under plasma concentration-time curve from zero to infinity (AUCinf)

    To compare the PK of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment to those with normal hepatic function

    Time frame: Day 1 to Day 5

  3. Maximum observed plasma concentration (Cmax)

    To compare the PK of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment to those with normal hepatic function

    Time frame: Day 1 to Day 5

Secondary outcomes

  1. AEs and SAEs up to the follow-up telephone call (Day 10 [± 3 days])

    To assess the safety and tolerability of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment and those with normal hepatic function

    Time frame: Screening (day -28 to day -2) to day 10

  2. Number of participants with abnormal Vital signs, abnormal ECGs, and abnormal physical examination findings

    To assess the safety and tolerability of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment and those with normal hepatic function

    Time frame: Screening (day -28 to day -2) to day 4

  3. Number of participants with abnormal laboratory tests results

    To assess the safety and tolerability of a single oral dose of balcinrenone in participants with mild and moderate hepatic impairment and those with normal hepatic function

    Time frame: Screening (day -28 to day -2) to day 4

07

Study locations

3 sites
  • Research Site
    Hialeah, Florida 33014, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Sep 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 29, 2024
StartActual
May 2, 2024
Primary completionActual
Sep 5, 2024
CompletionActual
Sep 5, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388616
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
May 2, 2024
Primary completion
Sep 5, 2024
Completion
Sep 5, 2024
Last update
Nov 12, 2024

Study contacts

Thomas C Marbury, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares
Eric J Lawitz, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares
Juan C Rondon, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion